Page 15 - Read Online

Tyerman et al. J Cancer Metastasis Treat 2022;8:29 https://dx.doi.org/10.20517/2394-4722.2022.20 Page 9 of 9

16. Gorgannezhad L, Umer M, Islam MN, Nguyen NT, Shiddiky MJA. Circulating tumor DNA and liquid biopsy: opportunities,
challenges, and recent advances in detection technologies. Lab Chip 2018;18:1174-96. DOI PubMed
17. Hindson BJ, Ness KD, Masquelier DA, et al. High-throughput droplet digital PCR system for absolute quantitation of DNA copy
number. Anal Chem 2011;83:8604-10. DOI PubMed PMC
18. Myllykangas S, Ji HP. Targeted deep resequencing of the human cancer genome using next-generation technologies. Biotechnol Genet
Eng Rev 2010;27:135-58. DOI PubMed PMC
19. Bettegowda C, Sausen M, Leary RJ, et al. Detection of circulating tumor DNA in early- and late-stage human malignancies. Sci Transl
Med 2014;6:224ra24. DOI PubMed PMC
20. Diehl F, Schmidt K, Choti MA, et al. Circulating mutant DNA to assess tumor dynamics. Nat Med 2008;14:985-90. DOI PubMed
PMC
21. Konishi F. CEA doubling time and CEA half-life in the prediction of recurrences after colorectal cancer surgery. Jpn J Clin Oncol
2002;32:41-2. DOI PubMed
22. Dawson SJ, Tsui DW, Murtaza M, et al. Analysis of circulating tumor DNA to monitor metastatic breast cancer. N Engl J Med
2013;368:1199-209. DOI PubMed
23. Diaz LA Jr, Williams RT, Wu J, et al. The molecular evolution of acquired resistance to targeted EGFR blockade in colorectal cancers.
Nature 2012;486:537-40. DOI PubMed PMC
24. Misale S, Yaeger R, Hobor S, et al. Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer.
Nature 2012;486:532-6. DOI PubMed PMC
25. Siravegna G, Mussolin B, Buscarino M, et al. Clonal evolution and resistance to EGFR blockade in the blood of colorectal cancer
patients. Nat Med 2015;21:795-801. DOI PubMed
26. Kim YW, Kim YH, Song Y, et al. Monitoring circulating tumor DNA by analyzing personalized cancer-specific rearrangements to
detect recurrence in gastric cancer. Exp Mol Med 2019;51:1-10. DOI PubMed PMC
27. Siravegna G, Bardelli A. Blood circulating tumor DNA for non-invasive genotyping of colon cancer patients. Mol Oncol 2016;10:475-
80. DOI PubMed PMC
28. Tie J, Kinde I, Wang Y, et al. Circulating tumor DNA as an early marker of therapeutic response in patients with metastatic colorectal
cancer. Ann Oncol 2015;26:1715-22. DOI PubMed PMC
29. Mohan S, Ayub M, Rothwell DG, et al. Analysis of circulating cell-free DNA identifies KRAS copy number gain and mutation as a
novel prognostic marker in Pancreatic cancer. Sci Rep 2019;9:11610. DOI PubMed PMC
30. Sugimori M, Sugimori K, Tsuchiya H, et al. Quantitative monitoring of circulating tumor DNA in patients with advanced pancreatic
cancer undergoing chemotherapy. Cancer Sci 2020;111:266-78. DOI PubMed PMC
31. Kruger S, Heinemann V, Ross C, et al. Repeated mutKRAS ctDNA measurements represent a novel and promising tool for early
response prediction and therapy monitoring in advanced pancreatic cancer. Ann Oncol 2018;29:2348-55. DOI PubMed
32. Lee B, Lipton L, Cohen J, et al. Circulating tumor DNA as a potential marker of adjuvant chemotherapy benefit following surgery for
localized pancreatic cancer. Ann Oncol 2019;30:1472-8. DOI PubMed PMC
33. Pietrasz D, Pécuchet N, Garlan F, et al. Plasma circulating tumor DNA in pancreatic cancer patients is a prognostic marker. Clin
Cancer Res 2017;23:116-23. DOI PubMed
34. Groot VP, Mosier S, Javed AA, et al. Circulating tumor DNA as a clinical test in resected pancreatic cancer. Clin Cancer Res
2019;25:4973-84. DOI PubMed PMC
35. Kim MK, Woo SM, Park B, et al. Prognostic implications of multiplex detection of. KRAS ;64:726-34. DOI PubMed
36. Däbritz J, Preston R, Hänfler J, Oettle H. Follow-up study of K-ras mutations in the plasma of patients with pancreatic cancer:
correlation with clinical features and carbohydrate antigen 19-9. Pancreas 2009;38:534-41. DOI PubMed
37. Steinberg WM, Gelfand R, Anderson KK, et al. Comparison of the sensitivity and specificity of the CA19-9 and carcinoembryonic
antigen assays in detecting cancer of the pancreas. Gastroenterology 1986;90:343-9. DOI PubMed
38. Wong T, Howes N, Threadgold J, et al. Molecular diagnosis of early pancreatic ductal adenocarcinoma in high-risk patients.
Pancreatology 2001;1:486-509. DOI PubMed
39. Wang ZY, Ding XQ, Zhu H, Wang RX, Pan XR, Tong JH. DOI PubMed PMC
40. Sausen M, Phallen J, Adleff V, et al. Clinical implications of genomic alterations in the tumour and circulation of pancreatic cancer
patients. Nat Commun 2015;6:7686. DOI PubMed PMC